Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets - GBI Research Reports

Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets

Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets - GBI Research Reports
Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets
Published Aug 31, 2011
196 pages — Published Aug 31, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets, which provides insights regarding the comparative analysis of marketed drugs based on safety, efficacy, cost of therapy and total sales revenue. The report also delves deep into the descriptions of every marketed drug, discussing their safety, efficacy, cost of therapy and clinical studies.

The in-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Researchs team of experts.

GBI Researchs analysis showed that the marketed drugs had to score highly in terms of safety and efficacy to ensure maximum usage. Patents assisted some of the marketed drugs in generating sales revenue devoid of competition, with some seeking patent extensions as well to ensure additional returns. However, patent expiries have resulted in a decline in the cost of therapy and revenue for some of the marketed drugs.

Scope

- Major indications with sizeable market share and growth.
- Comparative analysis of major marketed drugs in each of the major indications, in terms of safety, efficacy, cost of therapy and total sales revenue of the drugs.
- Detailed description of the drugs, including parameters such as safety, efficacy, cost of therapy and clinical studies.

Reasons to buy

The report will assist business development and help marketing executives to market products and strategize new product launches, by allowing them to -
- Differentiate their products from competitors in terms of safety, efficacy and cost of therapy.
- Invest in research to achieve novelty in treatment with an acceptable safety and efficacy profile; and obtain patents for ensuring monopoly business.
- Exploit licensing and acquisition opportunities by identifying products that might meet their expected returns.
- Focus on the addition of new indications to the existing ones, and different dosage forms for patient compliance.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Build effective strategies to market their products.
- Develop market-entry and market-expansion strategies by identifying the indications poised for strong growth.

  
Source:
Document ID
GBIHC113MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents44
  List of Tables71
Comparative Analysis of Marketed Drugs in Major Indications Introduction81
  GBI Research Report Guidance81
Comparative Analysis of Marketed Drugs in Major Indications Cardiovascular933
  Pulmonary Arterial Hypertension (PAH)91
    Comparative Analysis93
      Safety121
      Efficacy121
      Annual Cost of Therapy131
      Total Sales Revenue (2009)131
    Tracleer131
      Overview131
      Efficacy131
      Safety141
      Annual Cost of Therapy141
      Clinical Study Details141
    Remodulin151
      Overview151
      Efficacy151
      Safety151
      Annual Cost of Therapy161
      Clinical Study Details161
    Revatio161
      Overview161
      Efficacy161
      Safety171
      Annual Cost of Therapy171
      Clinical Study Details171
    Letairis181
      Overview181
      Efficacy181
      Safety181
      Annual Cost of Therapy181
      Clinical Study Details181
    Ventavis191
      Overview191
      Efficacy191
      Safety191
      Annual Cost of Therapy201
      Clinical Study Details201
    Adcirca201
      Overview201
      Efficacy201
      Safety201
      Annual Cost of Therapy211
      Clinical Study Details211
  Systemic Hypertension221
    Comparative Analysis222
      Safety241
      Efficacy241
      Annual Cost of Therapy251
      Total Sales Revenue (2009)251
    Diovan251
      Overview251
      Efficacy251
      Safety261
      Annual Cost of Therapy261
      Clinical Study Details261
    Cozaar261
      Overview261
      Efficacy261
      Safety261
      Annual Cost of Therapy271
      Clinical Study Details271
    Vasotec271
      Overview271
      Efficacy271
      Safety271
      Annual Cost of Therapy271
      Clinical Study Details271
    Lotension271
      Overview271
      Efficacy271
      Safety281
      Annual Cost of Therapy281
      Clinical Study Details281
    Norvasc281
      Overview281
      Efficacy281
      Safety281
      Annual Cost of Therapy281
      Clinical Study Details281
    Plendil291
      Overview291
      Efficacy291
      Safety291
      Annual Cost of Therapy291
      Clinical Study Details291
    Toprol-XL291
      Overview291
      Efficacy291
      Safety291
      Annual Cost of Therapy301
      Clinical Study Details301
    Tenormin301
      Overview301
      Efficacy301
      Safety301
      Annual Cost of Therapy301
      Clinical Study Details301
  Dyslipidemia311
    Comparative Analysis313
      Safety341
      Efficacy341
      Annual Cost of Therapy351
      Total Sales Revenue (2009)351
    Lipitor351
      Overview351
      Efficacy351
      Safety361
      Annual Cost of Therapy361
      Clinical Study Details361
    Vytorin361
      Overview361
      Efficacy361
      Safety371
      Annual Cost of Therapy371
      Clinical Study Details371
    Zetia371
      Overview371
      Efficacy371
      Safety371
      Annual Cost of Therapy371
      Clinical Study Details371
    Trilipix381
      Overview381
      Efficacy381
      Safety381
      Annual Cost of Therapy381
      Clinical Study Details381
    Simcor381
      Overview381
      Efficacy391
      Safety391
      Annual Cost of Therapy391
      Clinical Study Details391
    Lescol391
      Overview391
      Efficacy391
      Safety401
      Annual Cost of Therapy401
      Clinical Study Details401
    Livalo401
      Overview401
      Efficacy401
      Safety401
      Annual Cost of Therapy401
      Clinical Study Details411
    Lovaza411
      Overview411
      Efficacy411
      Safety411
      Annual Cost of Therapy411
      Clinical Study Details411
Comparative Analysis of Marketed Drugs in Major Indications Metabolic Disorders429
  Type 2 diabetes421
    Comparative Analysis421
      Safety431
      Efficacy441
      Annual Cost of Therapy441
      Total sales revenue (2009)441
    Actos441
      Overview441
      Efficacy451
      Safety451
      Annual Cost of Therapy451
      Clinical Study Details451
    Avandia451
      Overview451
      Efficacy451
      Safety461
      Annual Cost of Therapy461
      Clinical Study Details461
    Januvia461
      Overview461
      Efficacy461
      Safety461
      Annual Cost of Therapy461
      Clinical Study Details471
    Starlix471
      Overview471
      Efficacy471
      Safety471
      Annual Cost of Therapy471
      Clinical Study Details471
    Byetta481
      Overview481
      Efficacy481
      Safety481
      Annual Cost of Therapy481
      Clinical Study Details481
    Lantus491
      Overview491
      Efficacy491
      Safety491
      Annual Cost of Therapy491
      Clinical Study Details491
    Levemir491
      Overview491
      Efficacy491
      Safety501
      Annual Cost of Therapy501
      Clinical Study Details501
Comparative Analysis of Marketed Drugs in Major Indications Gastrointestinal5110
  Gastroesophageal Reflux Disease511
    Comparative Analysis513
      Safety541
      Efficacy541
      Cost of Therapy551
      Total Sales Revenue (2009)551
    Protonix551
      Overview551
      Efficacy551
      Safety551
      Cost of Therapy551
      Clinical Study Details551
    Nexium561
      Overview561
      Efficacy561
      Safety561
      Cost of Therapy561
      Clinical Study Details561
    Aciphex561
      Overview561
      Efficacy561
      Safety561
      Cost of Therapy561
      Clinical Study Details571
    Prevacid571
      Overview571
      Efficacy571
      Safety571
      Cost of Therapy571
      Clinical Study Details571
    Prilosec571
      Overview571
      Efficacy571
      Safety581
      Cost of Therapy581
      Clinical Study Details581
    Tagamet581
      Overview581
      Efficacy581
      Safety581
      Cost of Therapy581
      Clinical Study Details581
    Pepcid591
      Overview591
      Efficacy591

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets" Aug 31, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Comparative-Analysis-of-Marketed-Drugs-in-Major-Indications-Patent-Cliff-to-Set-Off-Intense-Price-Competition-in-High-Volume-Markets-2115-247>
  
APA:
GBI Research Reports. (2011). Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets Aug 31, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Comparative-Analysis-of-Marketed-Drugs-in-Major-Indications-Patent-Cliff-to-Set-Off-Intense-Price-Competition-in-High-Volume-Markets-2115-247>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.